Jacob Bastholm Olesen
Odense University Hospital
13 Papers
11 Citations
Jacob Bastholm Olesen is an academic researcher from Odense University Hospital. The author has contributed to research in topics: Osteoclast & Bone resorption. The author has an hindex of 5, co-authored 5 publications. Previous affiliations of Jacob Bastholm Olesen include University of Southern Denmark.
Chat about Author
Papers
Aging and menopause reprogram osteoclast precursors for aggressive bone resorption.
Anaïs Marie Julie Møller,Jean-Marie Delaissé,Jacob Bastholm Olesen,Jonna Skov Madsen,Luisa Matos do Canto,Troels Bechmann,Silvia Regina Rogatto,Kent Søe +7 more
TL;DR: It is concluded that monocytes are “reprogrammed” in vivo, allowing them to “remember” age, the menopausal status, and the bone formation status in vitro, resulting in more aggressive osteoclasts.
HepG2/C3A 3D spheroids exhibit stable physiological functionality for at least 24 days after recovering from trypsinisation
Krzysztof Wrzesinski,Maria Chiara Magnone,Line Visby Hansen,Marianne Ehrhorn Kruse,Tobias Bergauer,Maria Bobadilla,Marcel Gubler,Jacques Mizrahi,Kelan Zhang,Christina Møller Andreasen,Kira Joensen,Signe Marie Andersen,Jacob Bastholm Olesen,Ove B. Schaffalitzky de Muckadell,Stephen J. Fey +14 more
TL;DR: It is shown that after the recovery period, the 3D spheroid culture can provide a metabolically competent homeostatic cell model which is in equilibrium with its culture environment for more than 3 weeks.
Catabolic activity of osteoblast lineage cells contributes to osteoclastic bone resorption in vitro.
Dinisha Cyril Pirapaharan,Jacob Bastholm Olesen,Thomas Levin Andersen,Sandra Bjerre Christensen,Per Kjærsgaard-Andersen,Jean-Marie Delaissé,Kent Søe +6 more
TL;DR: It is shown that osteoclastic bone resorption becomes sensitive to inhibition of matrix metalloproteinases in the presence, but not in the absence, of osteoblast lineage cells, and it is proposed that this may be due to the direct action of osteooblast-lineage-derived MMP-13 on bone Resorption.
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals.
Anaïs Marie Julie Møller,Jean-Marie Delaissé,Jacob Bastholm Olesen,Troels Bechmann,Jonna Skov Madsen,Kent Søe +5 more
- 29 Sep 2020
TL;DR: There indeed is a high degree of variation in the potency of zoledronic acid on osteoclasts when generated from different individuals, and may therefore be of clinical importance, which should be investigated in a clinical trial combining in vitro and in vivo investigations.
18
GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells.
Morten Steen Hansen,Kent Søe,Line Julie Lindorf Christensen,Paula Fernández-Guerra,Nina Wærling Hansen,Rachael A. Wyatt,C. Martin,Rowan Hardy,Thomas Levin Andersen,Jacob Bastholm Olesen,Bolette Hartmann,Mette M. Rosenkilde,Moustapha Kassem,Alexander Rauch,Caroline M Gorvin,Morten Frost +15 more
TL;DR: In this paper , a GIPR-specific antagonist was used to assess whether GIP acts directly on primary human osteoclasts and osteoblasts, and the results indicated that drugs targeting GIPr may impair bone resorption, whilst preserving bone formation.
16